274 related articles for article (PubMed ID: 25768849)
1. A long-term study of istradefylline safety and efficacy in patients with Parkinson disease.
Kondo T; Mizuno Y;
Clin Neuropharmacol; 2015; 38(2):41-6. PubMed ID: 25768849
[TBL] [Abstract][Full Text] [Related]
2. Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces "off" time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005).
LeWitt PA; Guttman M; Tetrud JW; Tuite PJ; Mori A; Chaikin P; Sussman NM;
Ann Neurol; 2008 Mar; 63(3):295-302. PubMed ID: 18306243
[TBL] [Abstract][Full Text] [Related]
3. Adenosine A2A receptor antagonist istradefylline reduces daily OFF time in Parkinson's disease.
Mizuno Y; Kondo T;
Mov Disord; 2013 Jul; 28(8):1138-41. PubMed ID: 23483627
[TBL] [Abstract][Full Text] [Related]
4. Clinical efficacy of istradefylline (KW-6002) in Parkinson's disease: a randomized, controlled study.
Mizuno Y; Hasegawa K; Kondo T; Kuno S; Yamamoto M;
Mov Disord; 2010 Jul; 25(10):1437-43. PubMed ID: 20629136
[TBL] [Abstract][Full Text] [Related]
5. Istradefylline for Parkinson's disease patients experiencing motor fluctuations: results of the KW-6002-US-018 study.
Pourcher E; Fernandez HH; Stacy M; Mori A; Ballerini R; Chaikin P
Parkinsonism Relat Disord; 2012 Feb; 18(2):178-84. PubMed ID: 22000279
[TBL] [Abstract][Full Text] [Related]
6. Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations.
Hauser RA; Shulman LM; Trugman JM; Roberts JW; Mori A; Ballerini R; Sussman NM;
Mov Disord; 2008 Nov; 23(15):2177-85. PubMed ID: 18831530
[TBL] [Abstract][Full Text] [Related]
7. A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease.
Stacy M; Silver D; Mendis T; Sutton J; Mori A; Chaikin P; Sussman NM
Neurology; 2008 Jun; 70(23):2233-40. PubMed ID: 18519872
[TBL] [Abstract][Full Text] [Related]
8. Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD.
Hauser RA; Hubble JP; Truong DD;
Neurology; 2003 Aug; 61(3):297-303. PubMed ID: 12913187
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of Istradefylline, an Adenosine A2A Receptor Antagonist, as Adjunctive Therapy to Levodopa in Parkinson's Disease: A Pooled Analysis of 8 Phase 2b/3 Trials.
Hauser RA; Hattori N; Fernandez H; Isaacson SH; Mochizuki H; Rascol O; Stocchi F; Li J; Mori A; Nakajima Y; Ristuccia R; LeWitt P
J Parkinsons Dis; 2021; 11(4):1663-1675. PubMed ID: 34486986
[TBL] [Abstract][Full Text] [Related]
10. Safety and effectiveness of istradefylline in patients with Parkinson's disease: interim analysis of a post-marketing surveillance study in Japan.
Takahashi M; Fujita M; Asai N; Saki M; Mori A
Expert Opin Pharmacother; 2018 Oct; 19(15):1635-1642. PubMed ID: 30281377
[TBL] [Abstract][Full Text] [Related]
11. Adenosine A2A receptor antagonist istradefylline 20 versus 40 mg/day as augmentation for Parkinson's disease: a meta-analysis.
Zhu C; Wang G; Li J; Chen L; Wang C; Wang Y; Lin P; Ran H
Neurol Res; 2014 Nov; 36(11):1028-34. PubMed ID: 24725292
[TBL] [Abstract][Full Text] [Related]
12. Evaluating the impact of adjunctive istradefylline on the cumulative dose of levodopa-containing medications in Parkinson's disease: study protocol for the ISTRA ADJUST PD randomized, controlled study.
Hatano T; Kano O; Sengoku R; Yoritaka A; Suzuki K; Nishikawa N; Mukai Y; Nomura K; Yoshida N; Seki M; Matsukawa MK; Terashi H; Kimura K; Tashiro J; Hirano S; Murakami H; Joki H; Uchiyama T; Shimura H; Ogaki K; Fukae J; Tsuboi Y; Takahashi K; Yamamoto T; Yanagisawa N; Nagayama H
BMC Neurol; 2022 Mar; 22(1):71. PubMed ID: 35241003
[TBL] [Abstract][Full Text] [Related]
13. Istradefylline, an adenosine A₂A receptor antagonist, for patients with Parkinson's Disease: a meta-analysis.
Chen W; Wang H; Wei H; Gu S; Wei H
J Neurol Sci; 2013 Jan; 324(1-2):21-8. PubMed ID: 23085003
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of adenosine A2A receptor antagonist istradefylline as augmentation for Parkinson's disease: a meta-analysis of randomized controlled trials.
Tao Y; Liang G
Cell Biochem Biophys; 2015 Jan; 71(1):57-62. PubMed ID: 25096504
[TBL] [Abstract][Full Text] [Related]
15. The Efficacy of Istradefylline for Treating Mild Wearing-Off in Parkinson Disease.
Yabe I; Kitagawa M; Takahashi I; Matsushima M; Sasaki H
Clin Neuropharmacol; 2017; 40(6):261-263. PubMed ID: 28976411
[TBL] [Abstract][Full Text] [Related]
16. Istradefylline as monotherapy for Parkinson disease: results of the 6002-US-051 trial.
Fernandez HH; Greeley DR; Zweig RM; Wojcieszek J; Mori A; Sussman NM;
Parkinsonism Relat Disord; 2010 Jan; 16(1):16-20. PubMed ID: 19616987
[TBL] [Abstract][Full Text] [Related]
17. Istradefylline improves daytime sleepiness in patients with Parkinson's disease: An open-label, 3-month study.
Suzuki K; Miyamoto M; Miyamoto T; Uchiyama T; Watanabe Y; Suzuki S; Kadowaki T; Fujita H; Matsubara T; Sakuramoto H; Hirata K
J Neurol Sci; 2017 Sep; 380():230-233. PubMed ID: 28870576
[TBL] [Abstract][Full Text] [Related]
18. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study.
Parkinson Study Group
Arch Neurol; 2005 Feb; 62(2):241-8. PubMed ID: 15710852
[TBL] [Abstract][Full Text] [Related]
19. Preladenant as an Adjunctive Therapy With Levodopa in Parkinson Disease: Two Randomized Clinical Trials and Lessons Learned.
Hauser RA; Stocchi F; Rascol O; Huyck SB; Capece R; Ho TW; Sklar P; Lines C; Michelson D; Hewitt D
JAMA Neurol; 2015 Dec; 72(12):1491-500. PubMed ID: 26523919
[TBL] [Abstract][Full Text] [Related]
20. Occupancy of adenosine A
Ishibashi K; Miura Y; Wagatsuma K; Toyohara J; Ishiwata K; Ishii K
Neuropharmacology; 2018 Dec; 143():106-112. PubMed ID: 30253174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]